Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Tzu Tai

Showing results (171-180 of 211) with videos related to

Pageof 22
Sort By:
Leukemia|October 14, 2018
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cellsKrista Kinneer, Matt Flynn, Suneetha B Thomas, et al.
Blood Cancer Journal|November 5, 2020
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivoTengteng Yu, Bharat Chaganty, Liang Lin, et al.
Blood|September 14, 2014
Pyk2 promotes tumor progression in multiple myelomaYu Zhang, Michele Moschetta, Daisy Huynh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jawNoopur Raje, Sook-Bin Woo, Karen Hande, et al.
Blood Cancer Discovery|July 16, 2021
ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow MicroenvironmentGiada Bianchi, Peter G Czarnecki, Matthew Ho, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2016
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myelomaTeru Hideshima, Jun Qi, Ronald M Paranal, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disordersDaniel Ditzel Santos, Evdoxia Hatjiharissi, Olivier Tournilhac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2015
The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myelomaGang An, Zengjun Li, Yu-Tzu Tai, et al.
Blood|January 17, 2013
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionLian Xu, Zachary R Hunter, Guang Yang, et al.
Leukemia|October 9, 2019
Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myelomaGang An, Yuting Yan, Yan Xu, et al.
Pageof 22

Showing results (171-180 of 211) with videos related to

Sort By:
Pageof 22
Leukemia|October 14, 2018
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cellsKrista Kinneer, Matt Flynn, Suneetha B Thomas, et al.
Blood Cancer Journal|November 5, 2020
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivoTengteng Yu, Bharat Chaganty, Liang Lin, et al.
Blood|September 14, 2014
Pyk2 promotes tumor progression in multiple myelomaYu Zhang, Michele Moschetta, Daisy Huynh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jawNoopur Raje, Sook-Bin Woo, Karen Hande, et al.
Blood Cancer Discovery|July 16, 2021
ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow MicroenvironmentGiada Bianchi, Peter G Czarnecki, Matthew Ho, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2016
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myelomaTeru Hideshima, Jun Qi, Ronald M Paranal, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disordersDaniel Ditzel Santos, Evdoxia Hatjiharissi, Olivier Tournilhac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2015
The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myelomaGang An, Zengjun Li, Yu-Tzu Tai, et al.
Blood|January 17, 2013
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionLian Xu, Zachary R Hunter, Guang Yang, et al.
Leukemia|October 9, 2019
Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myelomaGang An, Yuting Yan, Yan Xu, et al.
Pageof 22